Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Eli Lilly and Company, the most common co-covered peer. We currently track 1 Biotech story that mention John F. Kuckelman, all published on July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Eli Lilly and Company, the most common co-covered peer. We currently track 1 Biotech story that mention John F. Kuckelman, all published on July 21, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering John F. Kuckelman. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit Filed
Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
FDA Approves Wegovy 7.2 mg
Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
The litigation underscores the GLP-1 dosing race: Wegovy 7.2 mg’s clinical superiority reshapes head-to-head comparisons, forcing Lilly to legally defend its ad strategy amid rapid innovation.
John F. Kuckelman is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
